Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
The University of Texas MD Anderson Cancer Center · University of Chicago · +34 more institutions
Abstract
Data are limited regarding the use of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors, such as veliparib, in combination with chemotherapy followed by maintenance as initial treatment in patients with high-grade serous ovarian carcinoma.
-mutation cohort), and the intention-to-treat population.
-mutation cohort, the median progression-free survival was 34.7 months in the veliparib-throughout group and 22.0 months in the control group (hazard ratio for progression or death, 0.44; 95% confidence interval [CI], 0.28 to 0.68; P
Citation impact
- FWCI
- 53.63
- Percentile
- 100%
- References
- 43
Authors
32- RLRobert L. ColemanCorresponding
The University of Texas MD Anderson Cancer Center
- GFGini F. Fleming
University of Chicago
- MFMark F. Brady
Roswell Park Comprehensive Cancer Center, NRG Oncology
- EMElizabeth M. Swisher
Seattle Cancer Care Alliance, University of Washington
- KDKarina Dahl Steffensen
University of Southern Denmark
Topics & keywords
- Veliparib
- Medicine
- Internal medicine
- Hazard ratio
- PARP inhibitor
- Oncology
- Carboplatin
- Population
- Good health and well-being